Latest Breaking News On - Derek jantz - Page 5 : comparemela.com

Precision BioSciences and Novartis Enter In Vivo Gene Editing Collaboration Targeting Rare Blood Disorders

Precision BioSciences and Novartis Enter In Vivo Gene Editing Collaboration Targeting Rare Blood Disorders
globalgenes.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalgenes.org Daily Mail and Mail on Sunday newspapers.

United statesJay bradnerMichael amorosoNovartis pharmaDerek jantzNovartis institutes for biomedical researchNovartis institutes

Precision BioSciences (DTIL) Announces In Vivo Gene Editing Collaboration with Novartis (NVS) to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease

Precision BioSciences (DTIL) Announces In Vivo Gene Editing Collaboration with Novartis (NVS) to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Jay bradnerMichael amorosoDerek jantzPrecision biosciences incNovartis institutes for biomedical researchWall streetNovartis pharmaChief executive officerNovartis institutesBiomedical researchChief scientific officer

Derek Jantz Sells 18,849 Shares of Precision BioSciences, Inc (NASDAQ:DTIL) Stock

Precision BioSciences, Inc. (NASDAQ:DTIL – Get Rating) insider Derek Jantz sold 18,849 shares of the firm’s stock in a transaction that occurred on Wednesday, June 8th. The shares were sold at an average price of $2.06, for a total transaction of $38,828.94. Following the sale, the insider now directly owns 4,055,174 shares of the company’s […]

United statesWilliam blairDerek jantzPrecision biosciences incPrecision biosciences company profile get ratingSecurities exchange commissionGoldman sachs group incZacks investment researchVanguard group incAcadian asset managementManagement coGoldman sachs groupDimensional fund advisorsPrecision biosciencesGet ratingExchange commission

Precision BioSciences (DTIL) Reports Publication of ARCUS In Vivo Gene Editing as a Promising Therapeutic Approach to Cure Chronic Hepatitis B Infection

Precision BioSciences (DTIL) Reports Publication of ARCUS In Vivo Gene Editing as a Promising Therapeutic Approach to Cure Chronic Hepatitis B Infection
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Mei burrisDerek jantzCassandra gorsuchMaurissa messierPrecision biosciences incGilead sciencesCorporate communicationsWall streetEliminate hepatitisb virus in vivoAcuitas therapeuticsGene editingComplex diseasesMolecular therapyChief scientific officerGene therapyPrecision biosciences

Precision BioSciences (DTIL) Reports Preclinical Data Showcasing Premier In Vivo Gene Editing Capabilities

Precision BioSciences (DTIL) Reports Preclinical Data Showcasing Premier In Vivo Gene Editing Capabilities
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesDerek jantzPrecision biosciences incAmerican society of gene cell therapyWaltere washington convention centerAmerican societyCell therapyConvention centerChief scientific officerHepatitisb surface antigenPresidential symposiumTop abstractsSustained transductionInfant macaque liverHydroxyacid oxidasePrimary hyperoxaluria type